All In Biotech

Drug Trial Radar · NCT04888728

To Evaluate Drug-drug Interactions Between DWN12088 and Nebivolol or Paroxetine in Healthy Volunteers

An Open Label, 2-part, One-sequence, 3-period Study to Evaluate Drug-drug Interactions Between "DWN12088" and "Nebivolol" or "Paroxetine" in Healthy Male Volunteers

Last checked: Nov 19, 2026Latest source record: Aug 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Jun 30, 2021

Primary completion

Jul 12, 2021

Study completion Jul 27, 2021

Sponsor

Sponsor type
Industry
First posted
May 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 20 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

An open label, 2-part, one-sequence, 3-period study to evaluate drug-drug interactions between DWN12088 and nebivolol or Paroxetine in healthy volunteers

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • DWN12088Drug

    Prolyl-tRNA synthetase (PRS) inhibitor

  • NebivololDrug

    Nebivolol

  • ParoxetineDrug

    Paroxetine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax of NebivololTime frame: Day 1, Day 2, Day 3, Day 6, Day 7, and Day 8
  2. AUCt of NebivololTime frame: Day 1, Day 2, Day 3, Day 6, Day 7, and Day 8
  3. Cmax of DWN12088Time frame: Day 1, Day 2, Day 3, Day 4, Day 9, Day 10, Day 11, and Day 12
  4. AUCt of DWN12088Time frame: Day 1, Day 2, Day 3, Day 4, Day 9, Day 10, Day 11, and Day 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Inje University Busan Paik Hospital

    Busan, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.